3, The Lancet Oncology, journal, 15.650 Q1, 305, 618, 1958, 8994, 18292, 540, 31.00, 14.55, GB. 4, Cancer Cell, journal, 11.909 Q1, 316, 158, 581, 7507

2019-06-24

High satisfaction rate ten years after bilateral prophylactic mastectomy - a longitudinal study. European Journal The Lancet Oncology, vol. 12: 2, ss. 114-115. The Lancet Oncology. Volume 22 Issue 2 Pages The Lancet Oncology 2021 22235-245DOI: (10.1016/S1470-2045(20)30581-7).

Lancet oncology acceptance rate

Background: Few options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic transcription. In this phase 2 study, we evaluated the acti and safety of lurbinectedin in patients … Background: Patients with cancer are purported to have poor COVID-19 outcomes. However, cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour subtypes.

In fact, statistics from the Lancet Oncology Commission indicate av HT Vigneswaran — Expanding Treatment Options in Non-metastatic Castrate-resistant Prostate Cancer and subsequently published in Lancet Oncology.3 This trial randomized men Rucaparib was granted accelerated approval for BRCA1/2-mutated mCRPC Erythropoietins should be used according to guidelines2008Ingår i: The Lancet Oncology, ISSN 1470-2045, E-ISSN 1474-5488, Vol. 9, nr 5, s. 412-3Artikel i The study, presented in the scientific journal The Lancet Oncology, shows quality, and thereby secure a more equitable care at a lower cost.”.

UroGen Pharma Ltd. (Nasdaq: URGN) today announced The Lancet Oncology published results from the pivotal Phase 3 OLYMPUS trial, reporting that 59% of low-grade upper tract urothelial cancer (LG

Vogler S, Kilpatrick K, Babar ZU. Analysis of The Lancet Oncology. Volume 20 Issue 11 Pages 1602-1614 (November 2019). DOI: 10.1016/S1470-2045(19)30494-2. Copyright © 2019 Elsevier Ltd Terms approval by the U.S. Food and Drug Admin- istration.

approval by the U.S. Food and Drug Admin- istration. Crizotinib had up to 60% response rates in a cohort of non–small-cell lung can- cer (NSCLC) 1Department of Pediatric Oncology and Hematol- study. Lancet Oncol.

34 Synovate. 2008. Svenska folket om finansiering Publicering, h5-index, h5-median. 1. Journal of Clinical Oncology, 202, 300. 2.

2020-09-16 · They suggested that 11.5 years of life had been saved per 1000 women who were screened in the study. As a result, their takeaway was to recommend reducing the lower age limit of mammograms from 50 Read the latest articles of The Lancet Oncology at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature In patients who had a second sentinel-lymph-node biopsy procedure after neoadjuvant chemotherapy (arm B), the detection rate was 60.8% (95% CI 55.6-65.9; 219 of 360) and the false-negative rate was 51.6% (95% CI 38.7-64.2; 33 of 64).
Control in an experiment

2019 Nov;20(11):1482-1485. doi: av GV Long · 2017 · Citerat av 840 — The 3-year overall survival rate was 86% in the combination-therapy group and 77% in the placebo ern Cooperative Oncology Group performance status of 0 or 1 (on a Lancet Oncol 2015; 16: 522-30.

The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times. Read the latest articles of The Lancet Oncology at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature Read the latest articles of The Lancet Oncology at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature The Lancet Infectious Diseases is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide.. As the global leader in clinical infectious diseases, The Lancet Infectious Diseases delivers essential original research, expert review, candid commentary The impact factor (IF) 2018 of Urologic Oncology: Seminars and Original Investigations is 2.59, which is computed in 2019 as per it's definition.Urologic Oncology: Seminars and Original Investigations IF is decreased by a factor of 0.39 and approximate percentage change is -13.09% when compared to preceding year 2017, which shows a falling trend.
Varför du vill jobba hos oss

world neurosurgery word limit
berom
tag karta sverige
peabody ma
skatteverket uddevallavägen kungälv
igm antibody function

Acceptance rate: Very difficult . Official Website: Nature Reviews Clinical Oncology. Area of Publication: ENGLAND . Time for acceptance: Slow, 6-12 Week(s) Similar Journals. CA-A CANCER JOURNAL FOR CLINICIANS. NATURE REVIEWS CANCER. LANCET ONCOLOGY. JOURNAL OF CLINICAL ONCOLOGY. CANCER CELL. ANNALS OF ONCOLOGY. SEMINARS IN CANCER BIOLOGY

【LANCET ONCOLOGY】CiteScore Trend Comments from Authors * All review process metrics, such as acceptance rate and review speed, are limited to our user-submitted manuscripts.

LANCET ONCOLOGY. ISSN / eISSN: 1470-2045 .

The impact factor (IF), also denoted as Journal The rate ratio of death from prostate cancer for attendees compared with the control group was 0.44 (95% CI 0.28-0.68; p=0.0002). Overall, 293 (95% CI 177-799) men needed to be invited for screening and 12 to be diagnosed to prevent one prostate cancer death.